Auris Medical News Release
November 21 2017 - 8:01AM
Auris Medical to Report Third Quarter 2017 Financial Results and
Provide Business Update on Tuesday, November 28, 2017
Zug, Switzerland, November 21, 2017 - Auris
Medical Holding AG (NASDAQ: EARS), a clinical-stage company
dedicated to developing therapeutics that address important unmet
medical needs in otolaryngology, today announced that it will
provide a business update and report its financial results for the
third quarter of 2017 on Tuesday, November 28, 2017. Following the
announcement, Auris Medical's management team will host a live
conference call and webcast at 8:00 am Eastern Time (2:00 pm
Central European Time).
To participate in this conference call, dial 1-877-280-1254
(USA) or +1-646-254-3365 (International), and enter passcode
4997511. A live webcast of the conference call can be accessed in
the Investor Relations section of the Auris Medical website at
www.aurismedical.com. A replay will be available approximately two
hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical
company dedicated to developing therapeutics that address important
unmet medical needs in neurotology. The company is focused on the
Phase 3 development of treatments for acute inner ear hearing loss
(AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by
way of intratympanic administration with biocompatible gel
formulations. In addition, Auris Medical is developing intranasal
betahistine for the treatment of vertigo (AM-125) as well as
early-stage research and development projects. The Company was
founded in 2003 and is headquartered in Zug, Switzerland. The
shares of Auris Medical Holding AG trade on the NASDAQ Capital
Market under the symbol "EARS."
Investor contact: Daniel Ferry, LifeSci
Advisors, 1-617-535-7746, investors@aurismedical.com
Media contact: David Schull, Russo Partners,
1-858-717-2310, david.schull@russopartnersllc.com
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Auris Medical (NASDAQ:EARS)
Historical Stock Chart
From Apr 2023 to Apr 2024